Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

ScinoPharm Taiwan Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

23 Apr 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - ScinoPharm Taiwan Ltd (1789-TW)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

29 Apr 2016 Thomson Reuters Stock Report 11 $25.00

Scinopharm Taiwan Limited (1789) - Financial Analysis Review

Scinopharm Taiwan Limited (1789) - Financial Analysis Review Summary ScinoPharm Taiwan, Ltd. (ScinoPharm) is a pharmaceutical...

18 Apr 2016 GlobalData 47 $300.00

Wright Investors Service Comprehensive Report for Scinopharm Taiwan Limited

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

12 Apr 2016 Wright Reports 55 $75.00

Scinopharm Taiwan Limited (1789) - Financial Analysis Review

Scinopharm Taiwan Limited (1789) - Financial Analysis Review Summary ScinoPharm Taiwan, Ltd. (ScinoPharm) is a pharmaceutical...

15 Mar 2016 GlobalData 47 $300.00

ScinoPharm Taiwan (1789 TT); Gross Margin Growth in 2016

We see Chinese API companies gradually losing its price competitiveness due to newly promulgated environment regulations. Ind...

02 Mar 2016 MasterLink Securities Corporation 6 $58.00

神隆 (1789):2016年毛利率提升,常熟廠開始貢獻營收

產業趨勢對台廠有利,並擴入製劑擴大產值,長線成長動能無虞:中國原料藥廠因新環保法使價格優勢消失,印度品質則不穩定,在產業趨向良性競爭的態勢下,神隆營運將穩定成長;長期而言,新興國家如中國與拉美逐步升級為法規市場,而高品質的台廠將更受到國際藥廠的青睞,...

26 Feb 2016 MasterLink Securities Corporation 5 $35.00

Will Scinopharm Taiwan Limited Build Solid Long-Term Returns?

24 Feb 2016 Sadif Analytics Prime 12 $25.00

神隆(1789.TT)營運轉型效應持續發酵,惟評價合理,維持中立

投資建議維持中立:投資建議上,雖營運轉型效應持續發酵,惟就評價面而言,本益比達51倍,另若以2013年業績高峰期稅後淨利12.7億、最高市值686億元同比例計算2016年獲利相對市值,合理股價位於60元,距2/18收盤價56.1元上漲空間不大,故維持...

19 Feb 2016 SinoPac Sec Inv Service 5 $35.00

Scinopharm Taiwan Limited (1789) - Financial Analysis Review

Scinopharm Taiwan Limited (1789) - Financial Analysis Review Summary ScinoPharm Taiwan, Ltd. (ScinoPharm) is a pharmaceutical...

15 Dec 2015 GlobalData 45 $300.00